NCT06069778View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Pancreatic Cancer
Interventions
DRUG

BNT321 Dose Level 1

Intravenous infusion

DRUG

BNT321 Dose Level 2

Intravenous infusion

DRUG

mFOLFIRINOX

Intravenous infusion

DRUG

BNT321 RP2D

Intravenous infusion

Trial Locations (2)

29425

Medical University of South Carolina (MUSC), Charleston

90067

Valkyrie Clinical Trials, Los Angeles

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
lead

BioNTech SE

INDUSTRY